Lung Cancer | Topics

 
Adding Nivolumab to Chemotherapy Improves Outcomes in Resectable NSCLC
June 07, 2021

The addition of neoadjuvant nivolumab plus platinum-doublet chemotherapy significantly improved pathological complete response rates and showed a greater depth of pathological response compared with chemotherapy alone in patients with resectable non–small cell lung cancer.

Adjuvant Gefitnib Fails to Induce Superior DFS, OS Versus Chemo in EGFR-mutant NSCLC
June 06, 2021

Although adjuvant treatment with gefitinib delayed early relapse in patients with completely resected EGFR-mutant non–small cell lung cancer, the agent did not significantly improve disease-free survival or overall survival compared with cisplatin/vinorelbine.

Pralsetinib Shows Durable Anti-Tumor Activity in Study Update for RET+ Solid Tumors
June 06, 2021

Pralsetinib was well tolerated, while demonstrating robust and durable anti-tumor activity when treating heavily pretreated patients with multiple RET fusion–positive advanced solid tumors.